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ABSTRACT
Background: The SF-6D preference-based scoring system was developed
several years after the SF-12 and SF-36 instruments. A method to predict
SF-6D scores from information in previous reports would facilitate
backwards comparisons and the use of these reports in cost-effectiveness
analyses.
Methods: This report uses data from the 2001–2003 Medical Expendi-
tures Panel Survey (MEPS), the Beaver Dam Health Outcomes Survey, and
the National Health Measurement Study. SF-6D scores were modeled
using age, sex, mental component summary (MCS) score, and physical
component summary (PCS) score from the 2002 MEPS. The resulting
SF-6D prediction equation was tested with the other datasets for groups of
different sizes and groups stratiﬁed by age, MCS score, PCS score, sum of
MCS and PCS scores, and SF-6D score.
Results: The equation can be used to predict an average SF-6D score using
average age, proportion female, average MCS score, and average PCS
score. Mean differences between actual and predicted average SF-6D
scores in out-of-sample tests was -0.001 (SF-12 version 1), -0.013 (SF-12
version 2), -0.007 (SF-36 version 1), and -0.010 (SF-36 version 2).
Ninety-ﬁve percent credible intervals around these point estimates range
from 0.045 for groups with 10 subjects to 0.008 for groups with more
than 300 subjects. These results were consistent for a wide range of ages,
MCS scores, PCS scores, sum of MCS and PCS scores, and SF-6D scores.
SF-6D scores from the SF-36 and SF-12 from the same data set were found
to be substantially different.
Conclusions: Simple equation predicts an average SF-6D preference-based
score from widely published information.
Keywords: MCS, PCS, prediction, SF-6D, SF-36, SF-12.
Introduction
The SF-36 and SF-12 are two of the most widely used health
measurement instruments [1,2]. Results from the SF-36 can be
reported as eight health dimension scores. Results from the SF-36
and SF-12 can be reported as two summary scores: the mental
component summary (MCS) score and physical component
summary (PCS) score. These component scores are constructed
using normative values so the average score is 50 and the stan-
dard deviation of scores is 10. The most commonly used norma-
tive values were collected in the United States in 1990 (for
version 1) and 1998 (for version 2). The health dimension and
component scores, however, are not appropriate for use in cost-
effectiveness analyses (CEA). The US Panel on Cost-Effectiveness
in Health and Medicine recommended a single preference-based
score be used in CEA. A preference-based score, referred to as
“health utility,” is constructed so that full health is anchored at
1.0 and death is anchored at 0 [3].
To facilitate the use of SF-12 and SF-36 in CEA, several
groups have constructed equations which use results from the
SF-12 and SF-36 to predict a preference-based summary score
from a different health utility instrument. There are equations
which predict Quality of Well-being and Health Utility Index
Mark 2 scores from the eight health dimension scores of the
SF-36 [4,5]. There are also equations which predict EQ-5D and
Health Utilities Index Mark 3 scores from the MCS and PCS
scores of the SF-12 [6–10]. Because these equations predict scores
across different health measurement systems, the error associated
with them is large.
Recently, researchers developed a single, preference-based
score which can be directly calculated for SF-family called the
SF-6D. In 2004, Brazier et al published consistent models for
both the SF-36 and SF-12 [11]. The SF-6D health description
system uses a common subset of item responses from both
version 1 and version 2 of these instruments. This model was
published 14 years after the development of the SF-36 and 9
years after the development of the SF-12. Given the time differ-
ence between the SF-36/SF-12 development and the SF-6D devel-
opment, there are a substantial number of reports which include
the eight health dimension scores or MCS and PCS scores, but
not SF-6D scores. Ara and Brazier have developed an equation to
predict SF-6D preference-based score from the eight health
dimension scores from the SF-36 [12]. There is, however, no
published prediction equation based on MCS and PCS scores.
This report includes the develop an equation to predict an
average SF-6D score from group level demographics and vari-
ables commonly reported in the literature: average age, propor-
tion female, average MCS score, and average PCS score. The
equation was estimated using Bayesian methods, and credible
intervals are presented for these point estimates which include
both parameter estimate uncertainty and individual uncertainty.
This equation allows comparisons to previously published
studies when it is impractical to access individual level data to
directly calculate the SF-6D.
Data and Methods
Data for Equation Estimation
The equation was estimated using data from the Medical Expen-
ditures Panel Survey (MEPS) which includes the SF-12 [13].
MEPS is a nationally representative survey of health care utili-
zation and expenditures for the US noninstitutionalized civilian
population. MEPS is a 2-year panel survey, with an overlapping
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cohort design, taken from the National Health Interview Survey
cohort. MEPS over-samples Hispanics, blacks, functionally
impaired adults, children with activity limitations, working-age
adults predicted to have high medical expenditures, and individu-
als with incomes predicted to be less than 200% of the poverty
level. Each year, a new cohort is initiated and followed longitu-
dinally through a series of ﬁve in-person interviews at 6-month
intervals. Cross-sectional analyses combine information from
two MEPS cohorts. MEPS conducts interviews with one or more
persons per household who report on health care utilization,
expenditures, insurance coverage, and medical conditions for
each household member.
Beginning in 2000, MEPS included a self-administered ques-
tionnaire (SAQ) to obtain information that potentially would be
unreliable if reported by a proxy. The SAQ was distributed to all
adults aged 18 years old or older in eligible households partici-
pating in MEPS. The SAQ included the SF-12. For the equation
estimation, data was used from 2002 MEPS, which includes the
SF-12 version 1 (SF-12v1).
Data for Equation Testing
The resulting equation was evaluated using data from several
sources. The equation was evaluated for use with the SF-12v1
with data from 2001 MEPS. The equation was evaluated for
use with the SF-12 version 2 (SF-12v2) with data from 2003
MEPS.
Data from the Beaver Dam Health Outcomes Study
(BDHOS) includes the SF-36 version 1 (SF-36v1) [14]. The
BDHOS was a random subset of older adults sampled from the
Beaver Dam Eye Study [15], a community-based study of eye-
disease prevalence and risk factors in Beaver Dam, WI. BDHOS
included 1430 participants between January 1991 and July 1992.
These data were collected in face-to-face interviews.
Data from the National Health Measurement Study (NHMS)
includes the SF-36 version 2 (SF-36v2). NHMS was a random
digit dial, telephone survey of US adults aged 35–89 collected
between June 2005 and August 2006 with 3844 participants.
This survey over-sampled individuals of African-American
descent and individuals over age 65 to decrease sampling error in
these subgroups. This survey also included administration of the
EQ-5D, Health Utilities Index, and Quality of Well-Being Scale
[16].
From all surveys, respondents were included in this analysis
if they were aged 18 and older with known age and sex
who completed the entire SF instrument. Individuals over the
age of 85 in MEPS have a recorded age of 85 for increased
conﬁdentiality.
Variables
The SF-36 was developed for the Medical Outcomes Study and
the standard form for version 1 was published in 1990. The
SF-12, developed in 1995, is a standardized subset of questions
which most closely estimates the MCS and PCS scores of the
SF-36 [2]. Both instruments have two versions. When necessary,
the version of these instruments is indicated by postscripts (e.g.,
SF-12v1 and SF-12v2).
MCS and PCS scores are used in these analyses. MCS and
PCS scores can be calculated using all items from either version
of the SF-36 or SF-12. The SF-12 was constructed so that MCS
and PCS scores from this instrument would be equivalent to
those from the SF-36 [2]. These scores are constructed to have a
mean of 50 and a standard deviation of 10 using population
norms [1,2]. There are two widely used sets of US norms; the
1990 normative values are most often used with version 1
although the 1998 normative values are most often used with
version 2. The normative values used to calculate the MCS
and PCS scores are indicated by subscripts (e.g., MCS1990 and
MCS1998). A simple correction can be used to compare MCS and
PCS scores using different US population norms. These correc-
tions are Eqs. 1 and 2 [1].
PCS PCS1990 1998 1 07897= − . (1)
MCS MCS1990 1998 0 16934= + . (2)
The SF-6D is computed using 11 items from the SF-36 or 7 items
from the SF-12.[11] When necessary, the version of the SF-6D is
indicated by subscripts (i.e., SF-6D12 and SF-6D36). The items are
used to describe six health domains: physical functioning, role
limitations, social functioning, pain, mental health, and vitality.
These domains have four to six levels which allows for 18,000
unique health states—a health state is a speciﬁc combination of
levels across the six domains. A household sample of adults from
the United Kingdom (n = 611) provided standard gamble valua-
tions for 249 SF-6D health states. These valuations were ﬁt in an
ordinary least squares regression to create an equation which can
be used to convert any combination of domain levels to an SF-6D
score. The maximum SF-6D12 score is 1.0 and the minimum
score is 0.345 [11].
Age and sex variables are also used in these analyses. Age is
the respondent’s age in years and sex is indicated with a binary
variable called “female” which is 1 when the respondent is
female and 0 when the respondent is male.
Analyses
Part 1: Descriptive information. Average MCS, PCS, and SF-6D
scores were computed by age group for all datasets. For the
BDHOS and NHMS, scores were calculated using the full SF-36
and an extracted SF-12. These averages were calculated using
STATA (version 10.0, StataCorp, College Station, TX) to allow
application of the sampling and poststratiﬁcation weights in the
MEPS and poststratiﬁcation weights in NHMS. Use of these
weights yields nationally representative estimates for non-
institutionalized civilian adults.
Part 2: SF-6D prediction equation development. SF-6D scores
were regressed on age, sex, MCS score, and PCS score from
the 2002 MEPS (SF-12v1) using WinBUGS 1.4.3 [17]. For
observations i, i = 1 . . . n: SF - 6Di = constant + bage(agei) +
bfemale(femalei) + bMCS(MCSi) + bPCS(PCSi) + ei, where each con-
stant, bage, bfemale, bMCS, and bPCS was assigned a noninformative
prior N(0, 1000). e is a normally distributed error term with
mean equal to zero and variance 1/t, where t was assigned a
noninformative prior, gamma (0.001, 0.001).
All models were considered which used subsets of these four
predictor variables and Deviance Information Criterion was used
as the model selection criterion [18]. The use of interaction or
power terms was excluded so that the equations can be used with
summary level statistics from previously published reports (see
results for more details). All models had three chains with a
10,000 iteration burnin and a 1000 iteration statistical sample
for the creation of a prediction equation and credible intervals.
These values are available from the author upon request. Model
convergence was assessed using the Gelman–Rubin statistic. The
SF-6D prediction equation was created using the means from the
posterior distribution of each parameter estimate from the best
model.
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Part 3: Creating credible intervals around estimates by sample
size (SF-12v1). Using data from the 2001 MEPS (SF-12v1), sub-
jects were randomly selected to form groups of 10, 20, 30, 400
observations. Each observation was combined with a random set
of estimates for each parameter and individual error drawn from
the posterior distribution of the best model from Part 2. These
parameter estimates were used to generate a predicted SF-6D
score for the observation. The difference between the actual and
average SF-6D score was calculated for each group. Using 500
repetitions for a particular group size, a 95% credible interval
was calculated.
Part 4: Testing the prediction equation for the SF-12v2, SF-36v1,
and SF-36v2. The analysis for Part 3 was repeated using data
from BDHOS (SF36-v1, SF-12v1), 2003 MEPS (SF-12v2), and
NHMS (SF-36v2, SF-12v2).
Part 5: Testing the prediction equation with restrictions on age,
MCS score, PCS score, the sum of MCS and PCS scores, and
SF-6D score. The analysis for Part 3 was repeated using data
from 2001 MEPS where group size was 50 observations and
group membership was restricted by age, MCS score, PCS score,
the sum of MCS and PCS scores, and SF-6D score. Age groups
included [20–25), [25–30), . . . [80–85), and 85 and over. MCS
score and PCS score groups included [15–20), [20–25), . . . [70–
75) for groups with more than 100 observations. The groups for
the sum of MCS and PCS scores included [40–55), [55–70), . . .
[100–115), and [115–117]. The differences between actual and
predicted average SF-6D scores for 500 groups were compared.
SF-6D group strata included [0.30–0.45), [0.325–0.475), [0.35–
0.5), [0.375–0.525), [0.40–0.45), [0.425–0.575), [0.45–0.6),
[0.475–0.625), [0.50–0.45), [0.525–0.675), [0.55–0.7), [0.575–
0.725), [0.60–0.45), [0.625–0.775), [0.65–0.8), [0.675–0.825),
[0.70–0.45), [0.725–0.875), [0.75–0.9), [0.775–0.925), [0.80–
0.45), [0.825–0.975), [0.85–1.0), [0.875–1.0), [0.90–1.0),
[0.925–1.0), and [0.95–1.0). Ten groups of 50 observations were
randomly selected from each of the strata.
Part 6: Comparison to previously published equations. There
are several previously published equations which predict a health
utility score from SF-family scores to other health measurement
systems such as the EQ-5D, Health Utilities Index, and Quality
of Well-Being Scale [4–10]. For the ﬁrst time in a nationally
representative survey, all of these health measurement systems
were simultaneously administered in the NHMS. Predicted and
observed health utility scores were compared for these different
equations using the 3386 respondents who completed all health
measurement systems in NHMS. Normalized root mean squared
error (NRMSE) was used for this comparison because the range
of health utility scores from each system is different.
Results
Part 1: Descriptive Information
All respondents in these surveys who were aged 18 and over with
known age, sex, MCS score, PCS score, and SF-6D score were
included in these analyses. This included 19,708 subjects from
2001 MEPS, 22,936 subjects from 2002 MEPS, 19,907 subjects
from 2003 MEPS, 1417 subjects from BDHOS, and 3739 sub-
jects from NHMS. Figure 1 illustrates the distribution of SF-6D
scores from each of these data sources. It illustrates that SF-6D
scores calculated from the SF-36 are more evenly distributed
over the range of SF-6D scores than those calculated from the
extracted SF-12 in the same data set. It also illustrates that SF-6D
scores became more evenly distributed over their range in MEPS
from the use of version 1 in 2002 to the use of version 2 in 2003.
The SF-6D does not show a ﬂoor effect in any of these general
population surveys with less than 1% of all respondents report-
ing the lowest scores. There are more respondents reporting the
highest SF-6D scores in these surveys with nearly 9% reporting
scores of 1.0 in NHMS.
Descriptive values from each sample are presented in Table 1
which allows for comparisons of the scores across age within
each survey, SF-12 scores across surveys, across versions of the
SF-12 within MEPS, and across SF-12 and SF-36 scores extracted
from the same dataset. Consistent with previous reports, PCS
and SF-6D scores decline with age (P < 0.001 for all surveys),
although MCS scores increase with age (P < 0.030 for all
surveys) [1,2,16].
Also consistent with previous reports, MCS, PCS, and SF-6D
scores are higher in NHMS than MEPS. These mean estimates
were created using sampling and poststratiﬁcation weights, so
both data sets purport to be representative of the US civilian,
noninstitutionalized population. As discussed by Hanmer et al.,
the difference in scores is most likely due to differences in mode
of administration; NHMS was a telephone interview and MEPS
was self-completed on paper and pencil. Likewise, SF-12v1
scores are higher in BDHOS than in 2002 MEPS, either because
the community sample used in BDHOS is healthier than MEPS or
because BDHOS was collected by an in-person interviewer and
MEPS was self-completed [19].
Comparing the SF-12v1 from 2002 MEPS and the SF-12v2
from 2003 MEPS shows that both MCS and PCS scores across
years and versions are within 1.1 of each other. After the correc-
tions from Eqs. 1 and 2, MCS scores are within 0.8 of each other
and PCS scores are within 0.7 of each other (data not shown).
SF-6D scores are within 0.021 of each other. Comparing SF-12 to
SF-36 scores from the same dataset shows that MCS scores from
the SF-36 are within 2.2 of MCS scores from the SF-12. Likewise,
PCS scores from the SF-36 are within 0.7 of the PCS scores from
the SF-12. SF-6D12 scores are larger than SF-6D36 scores from the
same dataset by as much as 0.042.
Part 2: SF-6D Prediction Equation Development
Given the substantial differences between SF-6D36 scores and the
SF-6D12 scores extracted from the same dataset, the relationship
between MCS and PCS scores to SF-6D scores will be dependent
onwhich version of the SF-6D is used. These analyses were limited
to models predicting the SF-6D12. The best ﬁtting model, using
Deviance Information Criterion, included all four predictor vari-
ables: age, female, MCS score, and PCS score (data not shown).
Using the mean of the posterior distribution for each param-
eter estimate, the best ﬁtting prediction equations are:
SF D
MCS
− = − − ( ) + ( )
+
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0 00946
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19
. . .
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+ −( )
.
. .PCS (4)
The mean of the posterior distribution for each parameter
estimate was the same as its median to ﬁve decimal places. The
95% credible intervals from the posterior distribution for the
parameter estimates were -0.06988–-0.5908 for the constant,
0.00008–0.00016 for age, -0.00460–-0.00195 for female,
0.00939–0.00953 for MCS, and 0.00774–0.00788 for PCS.
Note that Eqs. 3 and 4 predict the SF-6D12, regardless of the
use of SF-12 or SF-36 to calculate MCS and PCS. Equation 3 is
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most appropriate for studies which used version 1 of either the
SF-12 or SF-36, although Eq. 4 is most appropriate for studies
which used version 2 of either instrument.
Because the equations do not include interaction or power
terms, they can be used to predict an average SF-6D score using
average group information. Often, calculating an average score
for a group would require access to individual level data. For
example, using SF-6D12 with MCS and PCS scores normed to
1990 values could be calculated using Eq. 5.
1
6
1
0 06449 0 00328
0 00012
12
1 1n
SF D
n
i
i
n
i
n
− = − −[
+
= =
∑ ∑, . . ( )
.
female
age( ) + ( )
+ ( )]
0 00946
0 00781
1990
1990
.
.
,
,
MCS
PCS
i
i (5)
If individual level data are available, however, Eq. 5 would not be
useful because the SF-6D scores could be directly computed. This
equation is useful when only summary information is available,
such as the information published in a journal article. A simple
a b
c
e f g
d
Figure 1 Distribution of SF-6D scores from all data sources. Data from 2002 MEPS were used for equation estimation and all other data were used for equation
testing. (a) BDHOS SF-12v1. (b) NHMS SF-12v2. (c) BDHOS SF-36v1. (d) NHMS SF-36v2. (e) 2001 MEPS SF-12v1. (f) 2002 MEPS SF-12v1. (g) 2003 MEPS SF-12v2.
BDHOS, Beaver Dam Health Outcomes Survey; MEPS, Medical Expenditure Panel Survey; NHMS, National Health Measurement Survey.
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algebraic rearrangement, Eq. 6, creates an average SF-6D score
using the proportion female, average age, average MCS score,
and average PCS score from the sample:
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Part 3: Creating credible intervals around estimates by sample
size (SF-12v1). These equations provide a point estimate for the
average SF-6D score using group level statistics. The error of
this point estimate should depend on the original sample size.
Five hundred groups were created for each size. Sizes were 10,
20, 30, . . . , 400. The difference was calculated between the
true and predicted average SF-6D score from 2001 MEPS.
Table 2 lists the standard deviation of these differences and the
suggested 95% credible interval to use with groups of various
sizes. The estimate of an average SF-6D score from other
summary information becomes more accurate with larger
sample sizes, and this accuracy reaches an asymptote when
there are 300 or more subjects.
Table 1 Number of observations and average mental component summary (MCS), physical component summary (PCS), and SF-6D scores by age group
for the SF-36 and extracted SF-12 from the Beaver Dam Health Outcomes Survey (BDHOS) and National Health Measurement Survey (NHMS).Average
MCS, PCS, and SF-6D scores by age group for the SF-12 version 1 and version 2 from the 2002 and 2003 Medical Expenditure Panel Survey (MEPS). MCS
and PCS values were calculated using 1990 US population norms for BDHOS and 2002 MEPS.These values were calculated using 1998 US population norms
for NHMS and 2003 MEPS.Values from NHMS and MEPS were calculated using poststratiﬁcation weights making these estimates nationally representative
Unweighted number of respondents used in this report
BDHOS NHMS MEPS
1991–1992 1991–1992 2005–2006 2005–2006 2002 2003
Age group SF-36v1 SF-12v1 SF-36v2 SF-12v2 SF-12v1 SF-12v2
20–29 N/A N/A N/A N/A 4035 3662
30–39 N/A N/A 311 311 4621 3945
40–49 139 139 723 727 4765 4104
50–59 393 396 774 778 3707 3080
60–69 431 431 846 852 2352 2010
70–79 316 316 744 755 1684 1533
80+ 138 138 341 348 808 748
MCS mean(SE)
BDHOS NHMS MEPS
1991–1992 1991–1992 2005–2006 2005–2006 2002 2003
Age group SF-36v1 SF-12v1 SF-36v2 SF-12v2 SF-12v1 SF-12v2
20–29 N/A N/A N/A N/A 51.1 (0.2) 50.9 (0.2)
30–39 N/A N/A 52.9 (0.6) 53.4 (0.6) 51.1 (0.2) 50.6 (0.2)
40–49 53.3 (7.5) 52.5 (7.3) 52.9 (0.5) 53.0 (0.5) 50.6 (0.2) 50.5 (0.2)
50–59 54.6 (6.8) 53.7 (6.6) 53.7 (0.4) 53.7 (0.5) 50.7 (0.2) 50.6 (0.2)
60–69 56.1 (6.4) 54.8 (6.2) 55.2 (0.4) 55.1 (0.4) 52.3 (0.2) 52.4 (0.3)
70–79 55.5 (7.4) 54.3 (7.1) 54.9 (0.4) 54.9 (0.4) 52.3 (0.3) 52.0 (0.3)
80+ 56.2 (6.3) 54.0 (6.6) 54.9 (0.7) 55.3 (0.7) 51.1 (0.4) 50.1 (0.5)
PCS mean(SE)
BDHOS NHMS MEPS
1991–1992 1991–1992 2005–2006 2005–2006 2002 2003
Age group SF-36v1 SF-12v1 SF-36v2 SF-12v2 SF-12v1 SF-12v2
20–29 N/A N/A N/A N/A 53.4 (0.1) 54.5 (0.1)
30–39 N/A N/A 52.3 (0.6) 52.0 (0.6) 52.2 (0.1) 53.2 (0.1)
40–49 49.6 (9.1) 49.9 (8.6) 51.6 (0.4) 51.3 (0.4) 50.2 (0.2) 51.0 (0.2)
50–59 50.7 (7.8) 50.9 (7.7) 49.6 (0.5) 49.3 (0.5) 48.0 (0.2) 48.4 (0.2)
60–69 48.1 (9.5) 48.7 (9.2) 46.5 (0.6) 46.4 (0.6) 45.2 (0.3) 46.1 (0.3)
70–79 45.4 (9.8) 45.9 (9.6) 45.4 (0.6) 45.0 (0.7) 41.3 (0.3) 42.0 (0.4)
80+ 41.6 (12.0) 42.0 (11.9) 43.9 (0.9) 42.6 (0.9) 36.8 (0.5) 37.8 (0.6)
SF-6D mean(SE)
BDHOS NHMS MEPS
1991–1992 1991–1992 2005–2006 2005–2006 2002 2003
Age group SF-36v1 SF-12v1 SF-36v2 SF-12v2 SF-12v1 SF-12v2
20–29 N/A N/A N/A N/A 0.834 (0.002) 0.823 (0.003)
30–39 N/A N/A 0.802 (0.010) 0.833 (0.010) 0.826 (0.002) 0.810 (0.003)
40–49 0.787 (0.111) 0.825 (0.115) 0.798 (0.007) 0.823 (0.007) 0.807 (0.003) 0.793 (0.002)
50–59 0.808 (0.102) 0.846 (0.101) 0.790 (0.007) 0.817 (0.007) 0.793 (0.003) 0.772 (0.003)
60–69 0.803 (0.105) 0.845 (0.104) 0.778 (0.007) 0.812 (0.008) 0.790 (0.004) 0.776 (0.004)
70–79 0.782 (0.108) 0.820 (0.116) 0.766 (0.007) 0.795 (0.008) 0.763 (0.004) 0.745 (0.004)
80+ 0.743 (0.118) 0.775 (0.131) 0.758 (0.011) 0.787 (0.012) 0.709 (0.007) 0.691 (0.007)
N/A, not applicable.
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Part 4: testing the prediction equation for the SF-12v2, SF-36v1,
and SF-36v2. When out-of-sample tests were performed for
other versions of the SF instrument, several similarities and
differences emerged. The shape of the credible intervals across
group sizes was similar for all versions; the standard deviations
of differences between observed and predicted means decreased
as sample sizes increased and reached an asymptote around a
sample size of 300 observations. The standard deviation of these
differences was very similar for the SF-36v1 from BDHOS (an
average change of -0.2%) and slightly larger for both the
SF-12v2 from MEPS (an average change of 12.8%) and the
SF-36v2 from NHMS (an average change of 11.4%). The mean
difference in actual and predicted averages was very close to 0 for
the SF-36v1 from BDHOS (mean = -0.007) and larger for both
the SF-12v2 from MEPS (mean = -0.013) and SF-36v2 from
NHMS (mean = -0.010).
Part 5: testing the prediction equation with restrictions on age,
MCS Score, PCS Score, sum of MCS and PCS score, and SF-6D
score. Figure 2 illustrates the mean difference and root mean
squared error between actual average SF-6D scores and predicted
average SF-6D scores by various strata.Within each stratum, there
are 500 groups of 50 observations. Inclusion to the group was
restricted by age, MCS score, PCS score, or sum of MCS and PCS
score. For groups created from 2001 MEPS, age does not appear
to have an effect on predictive error or root mean squared error.
Just as in the overall comparisons fromPart 4, predictive errorwas
close to zero. There is a slight increase in error for those over the
age of 85, though the recorded age for all these respondents is 85
to increase conﬁdentiality in the public data set. Using groups
stratiﬁed byMCS score or PCS score createdmore predictive error.
It should be noted that these groups are very artiﬁcial as the range
of observed scores in any population, even a population with a
speciﬁc diagnosis, has substantial variation [4]. Predictive error
was close to zero andwell below the SF-6D’s minimally important
difference [20,21] for MCS and PCS scores from 20 to 60. Scores
at the extreme values of MCS and PCS, those below 20 and above
60, are associated with increased mean predictive error and root
mean squared error.However, the increase in error associatedwith
groups that have extreme values of summed MCS and PCS scores
is not as dramatic.
Figure 3 illustrates observed and predicted SF-6D scores for
groups of 50 observations. There is an over-prediction of mean
SF-6D scores for groups with observed mean SF-6D scores
between 0.5 and 0.8 and an under-prediction for groups with
observed mean SF-6D scores above 0.9.
Part 6: Comparison to previously published equations. Using
data from NHMS, the NRMSE of the equations developed in this
report perform better than all previously reported equations.
NRMSE was 0.070 when predicting the SF-6D12 from MCS12
and PCS12. Predictions of EQ-5D health utility scores also per-
formed well with NRMSE values of 0.077 [8], 0.078 [7], 0.082
[10], and 0.083 [6]. The NRMSE values for predictions of Health
Utilities Index scores were 0.092 [6], 0.093 [5], and 0.173 [9].
The NRMSE value for predictions of SF-6D scores using the
eight health dimension scores was 0.123 [12]. The NRMSE value
for predictions of Quality of Well-Being Scores was 0.137 [4].
Discussion
This report presents the development of an equation which can
be used to predict an average SF-6D12 score based on commonly
reported statistics in publications using the SF-12 or SF-36,
namely, average age, proportion female, average MCS score, and
average PCS score of any given sample. A credible interval for
this point estimate is dependent on the original sample’s size.
This equation is useful for predicting an SF-6D12 score when it is
impossible or impractical to obtain individual level data from
previously published studies. Use of these predicted SF-6D scores
is subject to the same limitations as directly calculated SF-6D
scores: limitations such as a known ﬂoor effect relative to other
health utility measurement systems [11].
This report includes several out-of-sample tests of this equa-
tion for both versions of the SF-36 and SF-12. In these tests,
mean predictive error was very close to zero for version 1 and
near -0.01 for version 2. Researchers and analysts using this
equation to predict an SF-6D score from reports of version 2
instruments may wish to adjust the prediction by -0.01 in sen-
sitivity analyses. Mean predictive error and root mean squared
error are similar across a large range of ages, MCS scores, PCS
scores, and the sums of MCS and PCS scores. Figure 2 illustrates
that root mean squared error increases for groups with a PCS
score below 20, PCS score above 60, and MCS score above 60.
There does not appear to be an increasing error when both MCS
and PCS scores are high or both are low as there are not large
changes in mean predictive error or root mean squared error at
the extreme ends of the range of summed MCS and PCS scores.
Development and testing of this equation was limited to
population-based data sets. Further validation in patient samples
would be appropriate as CEA is often concerned with very ill
populations. Such a validation could closely mimic the compila-
tion and analysis of health condition-based data sets presented by
Ara and Brazier [10,12]. For example, Boonen et al. [22] report
MCS, PCS, and SF-6D scores from a multicenter clinical trial of
patients with ankylosing spondylitis. The observed and predicted
mean SF-6D scores were 0.71 and 0.73 for the group receiving
Etanercept treatment and were 0.65 and 0.66 for the group
receiving placebo at the beginning of the extension study. These
results are consistent with Fig. 3 which illustrates that there may
be an over-prediction of mean SF-6D scores for groups with
observed mean SF-6D scores between 0.5 and 0.8. Figure 3 also
indicates there may be an under-prediction for groups with
observed mean SF-6D scores above 0.9, but no systematic differ-
ence for groups with observed mean SF-6D scores below 0.5.
Table 2 The standard deviation of differences between the true average
SF-6D score and the predicted SF-6D score for various group sizes using
SF-12 version 1 from 2001 Medical Expenditure Panel Survey. The sug-
gested credible interval around point estimates for a group size is the
standard deviation* 1.96
Group size
Standard deviation
of differences
Suggested 95%
credible interval
10 0.0230 0.045
20 0.0158 0.031
30 0.0129 0.025
40 0.0115 0.023
50 0.0106 0.021
60 0.0091 0.018
80 0.0081 0.016
100 0.0076 0.015
120 0.0064 0.013
140 0.0062 0.012
160 0.0055 0.011
180 0.0052 0.010
200 0.0049 0.010
220 0.0049 0.010
240 0.0045 0.009
260 0.0044 0.009
280 0.0044 0.009
>300 0.0041 0.008
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Figure 2 Average difference in observed and predicted SF-6D score and root mean squared error by age, mental component summary (MCS) score, physical
component summary (PCS) score, and summed MCS and PCS score. Each point represents 500 groups of 50 observations that were randomly selected from the
2001 MEPS. Inclusion in the groups was constrained by either age,MCS score, or PCS score.The difference between the observed average SF-6D score of the group
and the predicted average SF-6D score was calculated. This ﬁgure illustrates the mean of these differences with 95% conﬁdence intervals by age strata (a),MCS score
strata or PCS score strata (c), and sum of MCS and PCS score strata (e).This ﬁgure also illustrates the mean squared error of by age strata (b), MCS score strata
or PCS score strata (d), and sum of MCS and PCS score strata (f).
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CEA requires an estimate of the change in health utility from
one health state to another health state. CEA models can be
constructed using absolute health utility scores for a set of health
states. The change in health utility from one health state to
another is estimated as the difference in the absolute health utility
scores and only requires cross-sectional data. The prediction
equation proposed in this report sought to predict these absolute
health utility scores from cross-sectional data. CEA may also be
performed using the observed change in health utility scores from
longitudinal data. This report did not test the proposed equa-
tion’s ability to predict change scores. Recent reports by Ara and
Brazier have found that their prediction equations are reasonably
accurate at predicting out-of-sample incremental changes
[10,12]. It is unclear if their ﬁndings are generalizable to similar
prediction equations such as the one presented in this report.
The equation estimated in this report predicts an SF-6D score
based on seven items from the SF-12. These seven items are
present in both the SF-12 and SF-36. An SF-6D score can also be
calculated using 11 items from the SF-36. SF-6D36 score averages
were as much as 0.042 lower than SF-6D12 score averages in
BDHOS and NHMS. This difference may have a substantial
impact on analyses which combine absolute SF-6D scores from
different sources where some sources report SF-6D12 scores and
other sources report SF-6D36 scores. This observed difference in
absolute scores does not necessarily indicate that the longitudinal
changes in health utility measured by each of these scores would
be different. Researchers who have access to SF-36 data are
encouraged to extract and report absolute values and change
values for both the SF-6D12 and SF-6D36.
This equation can also be used with reports from the SF-36
which include mean scores for the eight health dimensions but
not MCS or PCS scores. Because MCS and PCS scores are a
linear combination of the eight health dimensions, mean MCS
and PCS scores can be directly calculated from mean scores for
the eight health dimensions using the same arithmetic logic as
presented in Part 2 of the results section [1,2]. There is also an
equation available which directly predicts SF-6D scores from the
eight health dimension scores [12].
As with most equations based on linear regression, there are
combinations of predictor variables which can generate nonsense
predictions. Possible observed SF-6D12 scores range from 0.345
to 1.0. The equation presented in this report would predict
SF-6D12 scores lower than 0.345 for a group with half females,
an average age of 50, and average MCS and PCS scores below
23. SF-6D12 scores higher than 1.0 would be predicted for a
group with half females, average age of 50, and average MCS
and PCS scores above 61. Although these scores are possible for
individuals, they are highly unlikely for group level statistics
because scores vary widely within any group of interest [4].
There are several other published equations to predict a
preference-based summary score from the SF-12 and SF-36
[4-9]. These equations, however, predict across instruments (e.g.,
SF-12 to EQ-5D) [6-8]. The equation presented in this report
predicts a summary score: the SF-6D, from a set of summary
scores (MCS and PCS) that are constructed using the same instru-
ment. As such, the equation presented in this report is associated
with less predictive error than previously published equations.
The equation presented in this report does have some predictive
error because the SF-6D is scored from a subset of items,
although MCS and PCS scores are constructed from all items in
the instrument. For example, in NHMS, NRMSE for the predic-
tion equation presented here was 0.070. Previously published
equations had NRMSEs from 0.077 [8] to 0.173 [9].
The subset of questions used to score the SF-6D from the
SF-36 or SF-12 may exhibit differential item functioning relative
to the unused questions. The prediction equation constructed in
this report uses information about the average age, proportion
female, average MCS score, and average PCS score for a group.
Age and sex were considered for model estimation because they
may cause differential item functioning. These variables were
found to improve model performance and were included in the
ﬁnal equation. The impact of age and sex on the relationship
between MCS and PCS scores to SF-6D scores is small, suggest-
ing a small amount of differential item functioning between the
questions used to score the SF-6D and all questions in the SF-12
and SF-36 instruments.
This report presents a simple equation to predict an average
SF-6D12 score from the average age, proportion female, average
MCS score, and average PCS score reported in other publications.
This equation provides a point estimate for the average SF-6D12
score and this report provides guidelines for assigning error to this
estimate based on the size of the original sample. This equation is
useful for estimating the SF-6D12 score for CEA which is using
estimates of health utility scores from previous reports when it is
impossible or impractical to access individual level data.
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Figure 3 Observed and predicted mean SF-6D scores for groups with 50
observations. This ﬁgure illustrates the mean observed and mean predicted
SF-6D scores for groups of 50 observations were randomly selected from the
2001 Medical Expenditure Panel Survey. SF-6D group strata included 0.30–0.45,
0.325–0.475, 0.35–0.5, 0.375–0.525, 0.40–0.45, 0.425–0.575, 0.45–0.6, 0.475–
0.625, 0.50–0.45, 0.525–0.675, 0.55–0.7, -0.575–0.725, 0.60–0.45, 0.625–0.775,
0.65–0.8, 0.675–0.825, 0.70–0.45, 0.725–0.875, 0.75–0.9, 0.775–0.925, 0.80–
0.45, 0.825–0.975, 0.85–1.0, 0.875–1.0, 0.90–1.0, 0.925–1.0, and 0.95–1.0. Ten
groups were randomly selected from each of the strata.
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